The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - ProteinSimple
Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ metastatic breast cancer.
 
Prashanth Reddy Moku
No Relationships to Disclose
 
Lois E. Shepherd
No Relationships to Disclose
 
Suhail Ali
No Relationships to Disclose
 
Kim Leitzel
No Relationships to Disclose
 
Wendy R. Parulekar
Consulting or Advisory Role - Pfizer
 
Liting Zhu
No Relationships to Disclose
 
Shakeel Virk
No Relationships to Disclose
 
Dora Nomikos
No Relationships to Disclose
 
Samuel Aparicio
Leadership - Contextual Genomics
Stock and Other Ownership Interests - Contextual Genomics
Consulting or Advisory Role - Contextual Genomics; Takeda
Research Funding - Takeda
Patents, Royalties, Other Intellectual Property - G-protein coupled receptor AU2002257927 (A1) Application filing date: 2002-05-16; G-protein coupled receptor AU2002307903 (A1) Application filing date: 2002-04-25; G-protein coupled receptor AU2002336181 (A1) Application filing date: 2002-10-21; GPR54 KNOCK-OUT MAMMALS AND SCREENING METHOD USING THEM SG155056 (A1) Application filing date: 2003-10-17; Gpr54 knock-out mammals and screening methods using them CN101173922 (A) Application filing date: 2003-10-17; Patent application filed June 21, 2005: Gpr100 receptor used in application of diabetes mellitus and obesity regulation. CN101031799 (A); Patent application Filed Mar. 16, 2010: Use of GPR100 Receptor in Diabetes and Obesity Regulation. US2010311077 (A1); Patent application filed Nov. 24, 2005: ION CHANNEL. WO2006059069 (A3); WO2006059069 (A2); Patent application filed Nov. 4, 2009: RECEPTOR. US2010272647 (A1); Patent application pending: Methods and Devices for Analyzing Particles Application #PCT/CA2016/0000031; RECEPTOR AT479708 (T) Application filing date: 2001-11-07; Receptor US2004025199 (A1) Application filing date: 2003-05-06; US Provisional Patent Filed Dec. 7, 2012 Predicting Treatment Response in Cancer Patients Application # 61734456; USE OF COMPOUNDS IN MEDICINE WO2004108119 (A3); WO2004108119 (A2) Application filing date: 2004-06-01; USE OF COMPOUNDS IN MEDICINE WO2004108141 (A3); WO2004108141 (A2) Application filing date: 2004-06-01
Travel, Accommodations, Expenses - Takeda
 
Karen A. Gelmon
Consulting or Advisory Role - AstraZeneca; Merck; Novartis; Pfizer
Expert Testimony - Genentech
 
Joseph Drabick
No Relationships to Disclose
 
Leah Cream
No Relationships to Disclose
 
Scott Halstead
No Relationships to Disclose
 
Hyma Vani Polimera
No Relationships to Disclose
 
Ashok Maddukuri
No Relationships to Disclose
 
Aamnah Ali
No Relationships to Disclose
 
Joyson Poulose
No Relationships to Disclose
 
Howard Spiegel
No Relationships to Disclose
 
Bingshu E. Chen
No Relationships to Disclose
 
Allan Lipton
Research Funding - Novartis (Inst)